Quince Therapeutics, Inc. (QNCX)
NASDAQ: QNCX · Real-Time Price · USD
2.080
+0.240 (13.04%)
At close: Nov 21, 2024, 4:00 PM
2.000
-0.080 (-3.84%)
After-hours: Nov 21, 2024, 5:58 PM EST
Quince Therapeutics Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
TTM
| FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
Sep '24 Sep 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 |
Selling, General & Admin | 15.91 | 15.4 | 24.91 | 29.52 | 17.59 | 8.95 | |
Research & Development | 16 | 9.25 | 25.18 | 60.8 | 61.31 | 30.21 | |
Operating Expenses | 31.9 | 24.64 | 50.09 | 90.32 | 78.89 | 39.17 | |
Operating Income | -31.9 | -24.64 | -50.09 | -90.32 | -78.89 | -39.17 | |
Interest & Investment Income | 3.41 | 3.48 | 1.07 | 0.62 | 2.04 | 2.19 | |
Currency Exchange Gain (Loss) | 0 | 0 | -0.77 | -0.25 | - | - | |
Other Non Operating Income (Expenses) | -1.24 | -0.34 | - | - | - | - | |
EBT Excluding Unusual Items | -29.74 | -21.5 | -49.79 | -89.95 | -76.85 | -36.98 | |
Merger & Restructuring Charges | -2.5 | -2.5 | -1.1 | - | - | - | |
Impairment of Goodwill | -17.13 | - | -0.83 | - | - | - | |
Gain (Loss) on Sale of Assets | -0.04 | -0.04 | -0.09 | - | - | - | |
Asset Writedown | -0.07 | -5.97 | -0.14 | - | - | - | |
Other Unusual Items | -3.66 | -1.58 | - | - | - | - | |
Pretax Income | -53.13 | -31.58 | -51.94 | -89.95 | -76.85 | -36.98 | |
Income Tax Expense | 0.13 | -0.2 | -0.28 | - | - | - | |
Net Income | -53.26 | -31.39 | -51.66 | -89.95 | -76.85 | -36.98 | |
Net Income to Common | -53.26 | -31.39 | -51.66 | -89.95 | -76.85 | -36.98 | |
Shares Outstanding (Basic) | 43 | 37 | 33 | 30 | 29 | 19 | |
Shares Outstanding (Diluted) | 43 | 37 | 33 | 30 | 29 | 19 | |
Shares Change (YoY) | 18.71% | 11.17% | 12.71% | 1.86% | 53.30% | 466.06% | |
EPS (Basic) | -1.25 | -0.84 | -1.54 | -3.03 | -2.63 | -1.94 | |
EPS (Diluted) | -1.25 | -0.84 | -1.54 | -3.03 | -2.63 | -1.94 | |
Free Cash Flow | -30.58 | -18.45 | -44.17 | -63.11 | -50.87 | -33.33 | |
Free Cash Flow Per Share | -0.72 | -0.50 | -1.32 | -2.12 | -1.74 | -1.75 | |
EBITDA | -31.43 | -24.32 | -49.89 | -89.97 | -78.56 | -38.98 | |
D&A For EBITDA | 0.47 | 0.32 | 0.2 | 0.34 | 0.33 | 0.19 | |
EBIT | -31.9 | -24.64 | -50.09 | -90.32 | -78.89 | -39.17 | |
Source: S&P Capital IQ. Standard template.
Financial Sources.